Cellyan Biotechnology Co., Ltd (HKPD) Stock Overview
Explore Cellyan Biotechnology Co., Ltd’s financial performance, market position, analyst ratings, and future outlook.
Cellyan Biotechnology Co., Ltd (HKPD)
Key Financials
Key Financials
Market Cap
4.6M
P/E Ratio
-6.15
EPS (TTM)
$-0.06
ROE
-0.14%
HKPD Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cellyan Biotechnology Co., Ltd's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of HKPD on the NASDAQ shows an RSI of 50.51, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.04 for the NASDAQ listing.
Key metrics behind Cellyan Biotechnology Co., Ltd's NASDAQ-traded stock include a P/E ratio of -6.15 and a market capitalization of 4.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of HKPD on the NASDAQ.